Stockscreener 앱 받기
4.43
2.78%
0.12
시간 외 거래:
4.43
Foghorn Therapeutics Inc 주식(FHTX)의 최신 뉴스
JMP Securities Reiterates Market Outperform Rating for Foghorn Therapeutics (NASDAQ:FHTX) - Defense World
Foghorn Therapeutics Inc. (FHTX) Reports Q1 Loss, Misses Revenue Estimates - MSN
FHTX: JMP Securities Reiterates Market Outperform Rating for Fog - GuruFocus
FHTX: JMP Securities Reiterates Market Outperform Rating for Foghorn Therapeutics | FHTX Stock News - GuruFocus
Foghorn Therapeutics Reports Q1 2025 Financial Results - TipRanks
Foghorn Therapeutics Provides First Quarter 2025 Financial and Corporate Update - GlobeNewswire
Foghorn Therapeutics: Pioneering Precision Medicine with Innovative Pharmacology and AI Integration - TipRanks
Foghorn Therapeutics Inc. reports results for the quarter ended March 31Earnings Summary - TradingView
FHTX Exceeds Revenue Expectations and Advances Pipeline Programs - GuruFocus
Foghorn Therapeutics Advances FHD-909 Phase 1 Trial - TipRanks
Foghorn Therapeutics Inc. SEC 10-Q Report - TradingView
Foghorn Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
Foghorn Therapeutics Advances Cancer Drug Pipeline with Strong Financial Results: Phase 1 Trial Shows Promise - Stock Titan
Foghorn Therapeutics Inc. (NASDAQ:FHTX) Holdings Boosted by Wells Fargo & Company MN - Defense World
Analysts Set Foghorn Therapeutics Inc. (NASDAQ:FHTX) PT at $12.13 - Defense World
Ted Myles Joins Cellarity as Chief Executive Officer - Stock Titan
Barclays PLC Increases Stock Position in Foghorn Therapeutics Inc. (NASDAQ:FHTX) - Defense World
(FHTX) Trading Advice - news.stocktradersdaily.com
Renaissance Technologies LLC Acquires 22,500 Shares of Foghorn Therapeutics Inc. (NASDAQ:FHTX) - Defense World
Foghorn Therapeutics’ SWOT analysis: chromatin pioneer’s stock faces clinical hurdles - Investing.com Nigeria
Foghorn Therapeutics to Participate in the Citizens Life Sciences Conference - GlobeNewswire
Foghorn Therapeutics (FHTX) Expected to Announce Quarterly Earnings on Monday - Defense World
JPMorgan Chase & Co. Purchases 45,565 Shares of Foghorn Therapeutics Inc. (NASDAQ:FHTX) - Defense World
Foghorn Therapeutics expands board with biotech veterans By Investing.com - Investing.com India
Foghorn Therapeutics expands board with biotech veterans - Investing.com
Foghorn Therapeutics Elects Neil Gallagher, M.D., Ph.D., and Stuart Duty to Board of Directors - Nasdaq
Foghorn Therapeutics Appoints Neil Gallagher and Stuart Duty to its Board of Directors - GlobeNewswire
Foghorn Therapeutics Presents New Preclinical Data on Selective - GuruFocus
Geode Capital Management LLC Boosts Stake in Foghorn Therapeutics Inc. (NASDAQ:FHTX) - Defense World
FHTX Unveils Promising Preclinical Data at Cancer Research Confe - GuruFocus
Foghorn Therapeutics Presents Preclinical Data at AACR 2025 - TipRanks
Foghorn Therapeutics Presents New Preclinical Data on Selective SMARCA2 Inhibitor FHD-909 and Selective CBP and Selective EP300 Degrader Programs and Provides Pipeline Update | FHTX Stock News - GuruFocus
Foghorn Therapeutics Presents New Preclinical Data on Selective SMARCA2 Inhibitor FHD-909 and Selective CBP and Selective EP300 Degrader Programs and Provides Pipeline Update - The Manila Times
Foghorn Therapeutics Presents New Preclinical Data on - GlobeNewswire
Breakthrough Cancer Drug FHD-909 Shows Synergy with Leading Treatments in Lung Cancer Studies - Stock Titan
Foghorn Therapeutics (NASDAQ:FHTX) Research Coverage Started at JMP Securities - Defense World
Foghorn Therapeutics (NASDAQ:FHTX) Earns Mkt Outperform Rating from Analysts at Citizens Jmp - Defense World
This PayPal Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Wednesday - Benzinga
JMP Securities Initiates Coverage of Foghorn Therapeutics (FHTX) with Market Outperform Recommendation - Nasdaq
Foghorn Therapeutics (FHTX) Gains Outperform Rating with $9 Targ - GuruFocus
Foghorn Therapeutics (FHTX) Gains Outperform Rating with $9 Target | FHTX Stock News - GuruFocus
Brokerages Set Foghorn Therapeutics Inc. (NASDAQ:FHTX) Price Target at $13.17 - Defense World
Foghorn Therapeutics to Host Virtual Investor Event to Review Pi - GuruFocus
Foghorn Therapeutics to Host Virtual Investor Event to Review Pipeline Updates in Conjunction with 2025 AACR Annual Meeting | FHTX Stock News - GuruFocus
Foghorn Therapeutics to Host Virtual Investor Event to - GlobeNewswire
Major Pipeline Breakthrough: Foghorn's First-in-Class Cancer Drug Shows Promise in NSCLC Treatment - Stock Titan
Foghorn Therapeutics Inc. (NASDAQ:FHTX) Shares Bought by Wellington Management Group LLP - Defense World
Foghorn Therapeutics (NASDAQ:FHTX) Stock Price Up 4.1% – Here’s What Happened - The AM Reporter
Foghorn Therapeutics (NASDAQ:FHTX) Trading 4.1% Higher – Time to Buy? - Defense World
Foghorn Therapeutics Inc. (NASDAQ:FHTX) Shares May Have Slumped 29% But Getting In Cheap Is Still Unlikely - simplywall.st
(FHTX) Technical Data - news.stocktradersdaily.com
Foghorn Therapeutics Inc. (FHTX) Reports Q4 Loss, Lags Revenue Estimates - MSN
1.54%
7.58%
자본화:
|
볼륨(24시간):